February 15, 2019
Weil advised Eli Lilly and Company in its $8 billion acquisition of Loxo Oncology, a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition is the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. The transaction closed February 15, 2019.
The Weil team that advised Eli Lilly was led by Mergers & Acquisitions partners Raymond Gietz and Matthew Gilroy and included Mergers & Acquisitions associates Aileen Kim, Stephen Liebscher, Mario Carroll and Bilal Chaudhry (Not Yet Admitted in New York); Technology & IP Transactions partner Jeffrey Osterman; Tax partner Helyn Goldstein; Executive Compensation & Benefits partner Amy Rubin; Patent Litigation and Life Sciences Co-Head Elizabeth Weiswasser; Regulatory counsel John O’Loughlin; Technology & IP Transactions associates Lauren Springer and Caleb Small (Not Yet Admitted in New York); Tax associate Eric Remijan; Executive Compensation & Benefits associates Amanda Rosenblum and Travis Bruno (Not Yet Admitted in New York); and Patent Litigation associates Aaron Pereira and Natalie Kennedy.